First Hawaiian Bank Has $931,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

First Hawaiian Bank reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 5.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,739 shares of the company’s stock after selling 854 shares during the period. First Hawaiian Bank’s holdings in AstraZeneca were worth $931,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. GAMMA Investing LLC lifted its position in shares of AstraZeneca by 21.1% in the first quarter. GAMMA Investing LLC now owns 3,559 shares of the company’s stock worth $241,000 after purchasing an additional 619 shares in the last quarter. Canandaigua National Bank & Trust Co. bought a new stake in AstraZeneca during the 1st quarter worth about $1,086,000. General Partner Inc. acquired a new position in shares of AstraZeneca during the 1st quarter worth about $52,000. HighPoint Advisor Group LLC bought a new position in shares of AstraZeneca in the 4th quarter valued at about $1,352,000. Finally, PNC Financial Services Group Inc. increased its position in shares of AstraZeneca by 1.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 234,341 shares of the company’s stock valued at $15,783,000 after acquiring an additional 3,225 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Up 0.2 %

AZN opened at $78.56 on Friday. The stock’s fifty day simple moving average is $76.10 and its 200 day simple moving average is $69.66. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $80.86. The stock has a market cap of $243.57 billion, a PE ratio of 38.51, a price-to-earnings-growth ratio of 1.41 and a beta of 0.48. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.08. The company had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. As a group, research analysts expect that AstraZeneca PLC will post 4.04 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. The Goldman Sachs Group initiated coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target for the company. BMO Capital Markets increased their price objective on AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, April 26th. Argus boosted their target price on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.